News

The first participants in a Phase 2 clinical trial testing brepocitinib, Roivant’s experimental oral treatment, in adults with cutaneous sarcoidosis have been dosed, and top-line results are expected in the second half of 2026. The company had this year announced plans to launch this proof-of-concept trial, called BEACON…

Methotrexate appears to take longer to start acting, but is no less effective than the corticosteroid prednisone as a first-line treatment for pulmonary sarcoidosis, according to the early findings of an ongoing Phase 4 clinical trial. The researchers noted that, while methotrexate treatment is associated with a similar number…

Many people with moderate or severe pulmonary sarcoidosis — the target market for the investigational therapy efzofitimod — are highly burdened by the disease and are dependent on corticosteroids that can have serious side effects, according to real-world analyses. “New real-world evidence underscores the growing burden of patients…

The prevalence of sarcoidosis, or the proportion of people with the condition in a population, has roughly doubled over the past 30 years in a region in Norway, a large population-based study shows, and the incidence of sarcoidosis, that is, the number of new cases within a given time,…

April has officially been recognized as Sarcoidosis Awareness Month in the U.S., marking a significant milestone for the community and its advocates, according to the Foundation for Sarcoidosis Research (FSR) — which also celebrates its 25th anniversary this year. The recognition by the U.S. Congress was spearheaded by Danny…

More than two dozen mutations that seem to increase the risk of developing sarcoidosis were identified in a new study. Notably, 17 of the 28 mutations hadn’t been linked to the inflammatory disease. Higher genetically predicted body mass index (BMI) and higher levels of several proteins involved in inflammation…

The findings of a new preclinical study in pulmonary sarcoidosis are lending support to the therapeutic potential of efzofitimod, a treatment candidate from Atyr Pharma now being tested in a Phase 3 clinical trial. The researchers found that a protein called HARS-WHEP — whose activity is mimicked by…

Nearly 1 in 10 people with pulmonary sarcoidosis also have heart involvement, or cardiac sarcoidosis, at the time of their initial diagnosis with the rare inflammatory disease occurring in the lungs, according to a study in Japan. Further, another 3.8% of patients subsequently develop cardiac sarcoidosis, the data…

The Foundation for Sarcoidosis Research (FSR) is partnering with Walgreens and Cedars-Sinai to provide free N95 face masks at two locations in Los Angeles, with the goal of helping members of the community protect their lungs following January’s wildfires. Exposure to fine particulate matter from soot and ash in…

April is Sarcoidosis Awareness Month, and this year’s theme, as chosen by the Foundation for Sarcoidosis Research (FSR), is “Facing Sarcoidosis Together” — which seeks to recognize the unique ways in which community, support, and advocacy can help patients navigate their disease. “Living with sarcoidosis presents significant challenges,…